Intercept Shares Soar 20% After FDA Announces Breakthrough Therapy Designation For NASH Drug By: TalkMarkets January 30, 2015 at 10:46 AM EST Intercept's OCA drug is designated a breakthrough therapy for treating a particular liver disease. Read More >> Related Stocks: Intercept Pharmaceuticals